CopyFind
Kavfix 200 LB Tablet
medicine 📍 IN

Kavfix 200 LB Tablet

145,00 ₹

Analogs of Kavfix 200 LB Tablet

Find cheaper analogs and generic equivalents for Kavfix 200 LB Tablet.

Ingredients

Princípio ativo: Cefixime; Lactobacillus (2.5Billion Spores)


Visão geral do produto

About Kavfix 200 LB Tablet

Kavfix 200 LB Tablet is a medication containing the active ingredient Cefixime, classified as Third-generation cephalosporin antibiotic. Cefixime, sold under the brand name Suprax among others, is an antibiotic medication used to treat a number of bacterial infections. These infections include otitis media, strep throat, pneumonia, urinary tract infections, gonorrhea, and Lyme disease.

Key Benefits & Uses

  • Used for: 1 INDICATIONS AND USAGE Cefixime for oral suspension is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric.
  • Use only as directed on the product label or by a healthcare professional.
  • Follow the authorised product information for dosing and duration of use.

Active Ingredient & Action

Cefixime, the active ingredient in Kavfix 200 LB Tablet, belongs to the Third-generation cephalosporin antibiotic class. 1 INDICATIONS AND USAGE Cefixime for oral suspension is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections (1. 1) Otitis Media (1. Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking Kavfix 200 LB Tablet. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use Kavfix 200 LB Tablet for extended periods without medical advice.

Find in Pharmacies

Compare local prices and distance for Kavfix 200 LB Tablet.

Visitor ratings

Help others by rating how useful this product page is.

No ratings yet — be the first.